Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 106 to 120 of 217 results for withdrawal

  1. Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (TA151)

    Evidence-based recommendations on continuous subcutaneous insulin infusion (insulin pump therapy) for treating type 1 diabetes in adults and children.

  2. Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over (TA1044)

    Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for treating severe sickle cell disease in people 12 years and over.

  3. Delirium in adults (QS63)

    This quality standard covers the prevention, diagnosis and management of delirium in adults (aged 18 and over) in hospital or long-term care settings (such as residential care or nursing homes). It describes high-quality care in priority areas for improvement.

  4. Post-traumatic stress disorder (NG116)

    This guideline covers recognising, assessing and treating post-traumatic stress disorder (PTSD) in children, young people and adults. It aims to improve quality of life by reducing symptoms of PTSD such as anxiety, sleep problems and difficulties with concentration. Recommendations also aim to raise awareness of the condition and improve coordination of care.

  5. Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (TA212)

    Evidence-based recommendations on bevacizumab (Avastin), with other drugs, for treating metastatic colorectal cancer in adults.

  6. Child abuse and neglect (QS179)

    This quality standard covers recognising, assessing and responding to abuse and neglect of children and young people under 18. It covers physical, sexual and emotional abuse. This quality standard describes high-quality care in priority areas for improvement.

  7. Interim clinical guideline surveillance process and methods guide 2013 (PMG16)

    This guide outlines the main elements of the interim NICE clinical guideline surveillance process and methodology, which was agreed by the NICE Board in July 2013

  8. Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (TA335)

    Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events, such as heart attack and stroke, after acute coronary syndrome in adults.

  9. Esketamine nasal spray for treatment-resistant depression (TA854)

    Evidence-based recommendations on esketamine (Spravato) for treatment-resistant depression in adults.

  10. Interim process and methods guide for the clinical guideline updates using standing committees pilot programme 2013 (PMG17)

    This guide outlines the main elements of the interim process and methods for the NICE clinical guideline updates using standing committees pilot programme, including details of the Clinical Guidelines Updates committee, which were agreed by the NICE Board in September 2013

  11. Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin (TA159)

    Evidence-based recommendations on spinal cord stimulation for chronic pain of neuropathic or ischaemic origin in adults.

  12. Setmelanotide for treating obesity caused by LEPR or POMC deficiency (HST21)

    Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity caused by LEPR or POMC deficiency in people 6 years and over.

  13. Child maltreatment: when to suspect maltreatment in under 18s (CG89)

    This guideline covers the signs of possible child maltreatment in children and young people aged under 18 years. It aims to raise awareness and help healthcare professionals who are not child protection specialists to identify the features of physical, sexual and emotional abuse, neglect and fabricated or induced illness.

  14. What is the clinical and cost effectiveness of opioids for the management of acute sciatica?

    benzodiazepines for long periods for sciatica. Given the potential harms from sudden withdrawal of these medicines, based on consensus,...

  15. What is the clinical and cost effectiveness of antidepressants for the management of sciatica?

    benzodiazepines for long periods for sciatica. Given the potential harms from sudden withdrawal of these medicines, based on consensus,...